June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Frequent subclinical macular changes in melanoma patients treated with combined BRAF/MEK inhibition and high dose hydroxychloroquine does not require dosing modification or discontinuation: preliminary results from a multi-institutional phase I/II clinical treatment trial for advanced metastatic BRAF mutant melanoma
Author Affiliations & Notes
  • Leona Serrano
    Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania , Philadelphia, Pennsylvania, United States
  • Harpal Sandhu
    Department of Ophthalmology, University of Louisville, Louisville, Kentucky, United States
  • Elaine Zhou
    Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania , Philadelphia, Pennsylvania, United States
  • Delu Song
    Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania , Philadelphia, Pennsylvania, United States
  • Tara Gangadhar
    University of Pennsylvania , Department of Medicine and Abramson Cancer Center, Philadelphia, Pennsylvania, United States
  • Lynn Schuchter
    University of Pennsylvania , Department of Medicine and Abramson Cancer Center, Philadelphia, Pennsylvania, United States
  • Sheryl Mitnick
    University of Pennsylvania , Department of Medicine and Abramson Cancer Center, Philadelphia, Pennsylvania, United States
  • Janice Mehnert
    The Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
  • Ann Silk
    The Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
  • Leonel Hernandez Aya
    Washington University, Department of Medicine and Siteman Cancer Center, St. Louis , Missouri, United States
  • Alexander Huang
    University of Pennsylvania , Department of Medicine and Abramson Cancer Center, Philadelphia, Pennsylvania, United States
  • Gerald Linette
    University of Pennsylvania , Department of Medicine and Abramson Cancer Center, Philadelphia, Pennsylvania, United States
  • Ravi K Amaravadi
    University of Pennsylvania , Department of Medicine and Abramson Cancer Center, Philadelphia, Pennsylvania, United States
  • Benjamin J Kim
    Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania , Philadelphia, Pennsylvania, United States
  • Tomas S Aleman
    Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania , Philadelphia, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Leona Serrano, None; Harpal Sandhu, None; Elaine Zhou, None; Delu Song, None; Tara Gangadhar, None; Lynn Schuchter, None; Sheryl Mitnick, None; Janice Mehnert, None; Ann Silk, None; Leonel Hernandez Aya, None; Alexander Huang, None; Gerald Linette, None; Ravi Amaravadi, None; Benjamin Kim, None; Tomas Aleman, None
  • Footnotes
    Support  National Institutes of Health (NEI-K12EY015398-10), Research to Prevent Blindness, Foundation Fighting Blindness, Hope for Vision, Macula Vision Research, the Paul and Evanina Bell Mackall Foundation Trust and The Pennsylvania Lions Sight Conservation
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 255. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Leona Serrano, Harpal Sandhu, Elaine Zhou, Delu Song, Tara Gangadhar, Lynn Schuchter, Sheryl Mitnick, Janice Mehnert, Ann Silk, Leonel Hernandez Aya, Alexander Huang, Gerald Linette, Ravi K Amaravadi, Benjamin J Kim, Tomas S Aleman; Frequent subclinical macular changes in melanoma patients treated with combined BRAF/MEK inhibition and high dose hydroxychloroquine does not require dosing modification or discontinuation: preliminary results from a multi-institutional phase I/II clinical treatment trial for advanced metastatic BRAF mutant melanoma. Invest. Ophthalmol. Vis. Sci. 2017;58(8):255.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To assess the potential ocular toxicity of a combined BRAF inhibition (BRAFi)/ MEK inhibition (MEki) /hydroxychloroquine (HCQ) regime used to treat advanced metastatic BRAF mutant melanoma.

Methods : Eight patients (31 to 69 years of age) with stage IV metastatic melanoma and BRAFV600E mutations were enrolled in a phase I/II clinical trial. Treatment was with oral dabrafenib, 150mg bid, trametinib, 2mg/day, and HCQ, 400-600mg bid. Ocular toxicity was assessed (at baseline, one month, q/6 months) by ophthalmic examination, spectral domain optical coherence tomography (SD-OCT), near infrared (NIR) and short-wavelength (SW) autofluorescence (FAF) imaging, and with visual acuity (VA) and light-adapted static perimetry (10-2 protocol).

Results : Treatment outcome was striking: 7/8 patients responded, 7/7 with a complete response; most remain on study at 12-18+ months. Ophthalmic examinations confirmed no safety concerns. 7/8 patients showed shallow separation of the photoreceptor outer segment (POS) tip from the apical retinal pigment epithelium (RPE), two with trace subretinal fluid (SRF) at the foveal center. Changes were mostly foveal but could be traced to the pericentral retina. Structural changes subsided without drug holiday/dose modification. There were no inner retinal abnormalities or photoreceptor loss or significant changes in VA or in foveal or mean sensitivity in any of the patients with these abnormalities. There were no changes in RPE melanization or lipofuscin content by NIR- and SW-FAF, respectively.

Conclusions : BRAF/MEK/HCQ treatment was well tolerated from an ocular toxicity standpoint. Frequent subclinical separation of the POS from the apical RPE without obvious SRF or changes in vision contrasts with the central serous-like retinopathy reported with single agent MEKi. SD-OCT changes may be related to transient interference with the RPE phagocytic or pump functions reflecting effective BRAF/MEK inhibition. The addition of BRAF inhibitor and/or HCQ to MEKi may ameliorate the retinal changes. Longer observation intervals in larger groups of patients treated with this regime are needed to confirm the prevalence and significance of the changes.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×